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Parenteral nutrition is often used in critically ill patients when enteral nutrition is not sufficient or is not fully installed. Lipid emulsions are an integral part of parenteral nutrition as they offer a high caloric density and prevent the fatty liver degeneration of long-term carbohydrate-based parenteral nutrition. Beyond use as a caloric source, lipids may influence the immune response. The standard lipid emulsion is based on soy bean oil (SO) supplying n-6 polyunsaturated fatty acids thought necessary to prevent essential fatty acid deficiency. In critically ill patients and in animal models, however, a negative impact of these lipid emulsions has been described. Barbosa and colleagues now report the effects of a new lipid emulsion on clinical and experimental parameters in patients with systemic inflammatory response syndrome and sepsis \[[@B1]\]. How do these effects integrate into our current concepts?

Use of SO-based lipid emulsions increases availability of free arachidonic acid, the precursor fatty acid of lipid mediators in septic patients \[[@B2]\]. A deterioration of the PaO~2~/FiO~2~ratio has been attributed to fast infusion (6 hours) instead of slow infusion (24 hours) of a SO-based lipid emulsion in patients with acute respiratory distress syndrome due to generation of arachidonic acid-derived prostaglandins and thromboxane \[[@B3]\]. In a simplified model, sepsis may be described as starting with a hyperinflammatory phase followed by a phase of immune suppression. When used early in septic patients, SO-based lipid emulsions have been shown to increase *ex vivo*cytokine generation in a small study \[[@B2]\]. These lipid emulsions also led to an increased apoptosis of splenic lymphocytes in a murine model, amplifying this key feature of immune suppression in late sepsis \[[@B4]\]. Recent European Society for Parenteral and Enteral Nutrition guidelines recommend using other available lipid emulsions with a reduced content of n-6 polyunsaturated fatty acids instead of SO-based lipid emulsions \[[@B5]\].

Addition of a pure fish oil (FO)-based emulsion to a non-FO-containing emulsion or use of FO-containing lipid emulsions may offer alternative options to provide lipids. With this approach a supply of n-3 fatty acids may be combined with a reduced deliverance of n-6 lipids. Interestingly, the recently discovered n-3 fatty acid-derived resolvins and protectins are key mediators for the active resolution of inflammatory processes and their application has shown improved outcome in a murine model of abdominal sepsis \[[@B6]\]. Results from smaller trials and multicenter trials including FO in the parenteral nutrition in patients after major surgery herald a good clinical benefit, including a reduced length of stay (for example, \[[@B7]\]).

A larger single-centre trial in 166 critically ill patients comparing a lipid emulsion based on SO and medium-chain triglycerides (LCT/MCT) versus the same emulsion supplemented with FO, however, failed to detect a clinical benefit \[[@B8]\]. This study was planned to detect a faster reduction in biomarkers modeled after the time course in postoperative patients; however, the authors failed to prove a significant reduction in both groups. A possible explanation may be that they started to use the lipid emulsions after the initial inflammatory process was already terminated. All secondary outcome parameters - such as, for example, infectious rate, length of stay, and mortality - were not significantly different.

This study is contrasted by the recent trial of Barbosa and coworkers \[[@B1]\]. They randomized 25 patients with systemic inflammatory response syndrome and sepsis to receive parenteral nutrition with a LCT/MCT emulsion or a LCT/MCT/FO lipid emulsion supplied continuously over 5 days, demonstrating a highly significant faster reduction in IL-6 in plasma in the LCT/MCT/FO group. In contrast to a previous study by Friesecke and colleagues \[[@B8]\], the patients had a higher mortality rate and were included earlier, exhibiting high IL-6 plasma concentrations at study entry. Barbosa and colleagues could also show a significantly faster improvement of the oxygenation parameter, as determined by the PaO~2~/FiO~2~ratio in the LCT/MCT/FO group. While other clinical outcome parameters were not different between the two groups, a trend for a shorter length of stay in hospital was found.

Keeping in mind the small number of patients included, the interesting data of the study are supported by another small trial in 40 critically ill patients with severe acute pancreatitis \[[@B9]\]. In a double-blind randomized study, 53 days of parenteral nutrition using a SO-based lipid emulsion was compared with SO (80% of the lipid component) with additional FO early in the course of the disease. The authors reported a significant reduced need for renal replacement therapy and a faster improvement in the PaO~2~/FiO~2~ratio in the SO/FO group. Furthermore, improved liver function was reported in critically ill patients when including a fraction of FO in the parenteral nutrition \[[@B10]\], and parenteral nutrition-associated liver disease was reversed in a cohort of children receiving long-term parenteral nutrition when exchanging a SO-based lipid emulsion for a FO-based lipid emulsion \[[@B11]\].

What may we conclude from the available data? It seems prudent to use lipid emulsions with a reduced fraction of n-6 polyunsaturated fatty acids as recommended by the European Society for Parenteral and Enteral Nutrition \[[@B5]\]. The effect of FO seems best when used early in critically ill patients. Most studies used between 0.1 and 0.2 g/kg/day FO as part of the parenteral nutrition. This assumption is supported by the analysis of a database in 661 critically ill patients, including patients with sepsis, where best outcome data were found in this dose range \[[@B12]\]. The promising data from Barbosa and colleagues in septic patients should lead to trials examining the effects of FO in larger cohorts of patients.
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